Follow the latest coverage, related explainers and connected technology stories.
Vijay Pande believes that artificial intelligence is changing drug development and precision medicine, but the lack of open biological data remains an obstacle to fulfilling its promise. At the same time, his new fund, VZVC, is betting on a limited number of focused investments instead of building a broad portfolio.